Proposals for Novel Formulations Based on Basic and Applied Research
First written in FY2016. 31 of 33 entries say "Restated". Latest entry: FY2027-H1.
1 other company's latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「The Group's research and development activities totaled ¥425 million during the interim consolidated accounting period. There were no material changes in the status of the Group's research and development activities during the period.」
The Company stated that there had been no material changes in research and development activities and reported research and development expenses of ¥425 million for the interim consolidated accounting period. - FY2026AdvancedAnnual report
「In creating new added value, the company is also focusing on developing technologies that combine its strengths in makeup technology with skincare technology. Some of the results are scheduled to be presented at IFSCC2026 (International Federation of Societies of Cosmetic Chemists), to be held in Australia in September 2026.」
In addition to proposing newly developed formulations based on basic and applied research, the company is pursuing the integration of makeup and skincare technologies and plans to present the results at IFSCC2026 in September 2026. - FY2026-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥412 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company reconfirmed that there had been no material changes in R&D activities and reported R&D expenses of ¥412 million for the interim consolidated accounting period. - FY2025-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥433 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company stated that there had been no material changes in R&D activities and reported R&D expenses of ¥433 million for the interim consolidated accounting period. - FY2025-Q1RestatedAnnual report
「The Group’s total R&D expenses for the cumulative first quarter were ¥208 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter.」
The company reconfirmed that there had been no material changes in R&D activities and reported R&D expenses of ¥208 million for the first quarter. - FY2024-Q3RestatedAnnual report
「The Group’s total R&D expenses for the cumulative third quarter were ¥548 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥548 million for the cumulative third quarter. - FY2024-Q2RestatedAnnual report
「The Group’s total R&D expenses for the cumulative second quarter were ¥365 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥365 million for the cumulative second quarter. - FY2024-Q1RestatedAnnual report
「R&D expenditure for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥175 million. There were no material changes in the status of the Group’s R&D activities during the period.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥175 million for the cumulative first quarter. - FY2023-Q3RestatedAnnual report
「The Group’s total R&D expenses for the cumulative third quarter were ¥491 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter.」
The company states that there were no material changes in its R&D activities and reports R&D expenses of ¥491 million for the cumulative third quarter. - FY2023-Q2RestatedAnnual report
「The Group’s total R&D expenses for the cumulative second quarter were ¥322 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter.」
The company states that there were no material changes in its R&D activities and reports R&D expenses of ¥322 million for the first-half cumulative period. - FY2023-Q1RestatedAnnual report
「The Group’s total R&D expenses for the cumulative first quarter were ¥162 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter.」
The company states that there were no material changes in its R&D activities and reports R&D expenses of ¥162 million for the quarter. - FY2022RestatedAnnual report
「Regarding the Group’s R&D activities, our basic policy is to promptly provide products that meet diverse, sophisticated and broad market needs in the cosmetics and quasi-drugs fields, while actively proposing newly developed formulations based on basic and applied research.」
The company maintained its basic R&D policy, and R&D expenses for the consolidated fiscal year were ¥610 million. - FY2022-Q3RestatedAnnual report
「The Group’s total R&D expenses for the cumulative third quarter were ¥460 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥460 million for the cumulative third quarter. - FY2022-Q2RestatedAnnual report
「The Group’s total R&D expenses for the cumulative second quarter were ¥290 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter.」
The company states that there were no material changes in its R&D activities and reports R&D expenses of ¥290 million for the first-half cumulative period. - FY2022-Q1RestatedAnnual report
「The Group's research and development activities amounted to ¥152 million during the first quarter of the current fiscal year. There were no material changes in the status of the Group's research and development activities during the first quarter of the current fiscal year.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥152 million for the first quarter. - FY2021RestatedAnnual report
「Regarding the Group’s R&D activities, our basic policy is to promptly provide products that meet diverse, sophisticated and broad market needs in the cosmetics and quasi-drugs fields, while actively proposing newly developed formulations based on basic and applied research.」
The company maintained its basic R&D policy of actively proposing newly developed formulations based on basic and applied research and recorded R&D expenses of ¥643 million. - FY2021-Q3RestatedAnnual report
「The Group’s total R&D expenses for the cumulative third quarter were ¥492 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥492 million for the cumulative third quarter. - FY2021-Q2RestatedAnnual report
「The Group’s total R&D expenses for the cumulative second quarter were ¥335 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥335 million for the first-half cumulative period. - FY2021-Q1RestatedAnnual report
「The Group’s total R&D expenses for the cumulative first quarter were ¥157 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥157 million for the cumulative first quarter. - FY2020RestatedAnnual report
「The total R&D expenses for the consolidated fiscal year were ¥726 million.」
The company adopted proposals for newly developed formulations based on basic and applied research as its basic policy and recorded full-year R&D expenses of ¥726 million. - FY2020-Q3RestatedAnnual report
「The amount spent on research and development activities by the Group during the third quarter of the current consolidated cumulative period was ¥554 million. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥554 million for the cumulative third quarter. - FY2020-Q2RestatedAnnual report
「The Group’s total R&D expenses for the cumulative second quarter were ¥371 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥371 million for the cumulative second quarter. - FY2020-Q1RestatedAnnual report
「The Group’s total R&D expenses for the cumulative first quarter were ¥174 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥174 million. - FY2019-Q3RestatedAnnual report
「Group-wide R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥539 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥539 million for the cumulative third quarter. - FY2019-Q2RestatedAnnual report
「The Group’s total R&D expenses for the cumulative second quarter were ¥360 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥360 million for the cumulative second quarter. - FY2019-Q1RestatedAnnual report
「Group-wide R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥181 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥181 million for the cumulative first quarter. - FY2018RestatedAnnual report
「Our basic policy is to promptly provide products that meet diverse and sophisticated market needs in the cosmetics and quasi-drug fields, while actively proposing newly developed formulations based on basic and applied research.」
The company reaffirmed its basic R&D policy of proposing newly developed formulations based on basic and applied research, and R&D expenses for the fiscal year were ¥640 million. - FY2018-Q3RestatedAnnual report
「The Group’s total R&D expenses for the cumulative third quarter were ¥489 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter.」
The company states that there were no material changes in the status of its R&D activities and reports R&D expenses of ¥489 million for the cumulative third quarter. - FY2018-Q2RestatedAnnual report
「The Group’s total R&D expenses for the cumulative second quarter were ¥321 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter.」
The company reaffirmed that there were no material changes in its R&D activities and reports R&D expenses of ¥321 million for the cumulative second quarter. - FY2018-Q1RestatedAnnual report
「The Group’s total R&D expenses for the cumulative first quarter were ¥157 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter.」
The company states that there were no material changes in its R&D activities and reports R&D expenses of ¥157 million for the first quarter. - FY2017RestatedAnnual report
「Our basic policy is to promptly provide products that meet diverse and sophisticated market needs in the cosmetics and quasi-drug fields, while actively proposing newly developed formulations based on basic and applied research.」
There were no material changes in the basic R&D policy, and R&D expenses for the fiscal year were ¥600 million. - FY2017-Q3RestatedAnnual report
「The Group's research and development expenditure for the nine-month period ended the third quarter was ¥461 million. There were no material changes in the status of the Group's research and development activities during the period.」
The company states that there were no material changes in its R&D activities and reports R&D expenses of ¥461 million for the cumulative third quarter. - FY2016First statedAnnual report
「Our basic policy is to promptly provide products that meet diverse and sophisticated market needs in the cosmetics and quasi-drug fields, while actively proposing newly developed formulations based on basic and applied research.」
The Company’s basic R&D policy is to address market needs and actively propose newly developed formulations.